Nectar Lifesciences (NSE:NECLIFE) FFO


NSE:NECLIFE Nectar Lifesciences Ltd NSE:NECLIFE
51 GF Score
Price ₹11.75
GF Value ₹6.81
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nectar Lifesciences FFO?

FFO (Funds from operations) only applies to REITs.

NSE:NECLIFE
51GF Score
Nectar Lifesciences Ltd NSE:NECLIFE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued. The current stock price of ₹11.75 is trading 72.5% above its estimated GF Value™ of ₹6.81. GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.

Key valuation signals for NSE:NECLIFE:

  • FFO:
  • GF Value™: ₹6.81 vs. price of ₹11.75 (72.5% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nectar Lifesciences Business Description

Other Exchanges 532649:India
Address S.C.O. 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
51GF Score

Get the complete analysis for NSE:NECLIFE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹11.75
Price
₹6.81
GF Value